These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 20571034

  • 1. Do drug transporter (ABCB1) SNPs influence cyclosporine and tacrolimus dose requirements and renal allograft outcome in the posttransplantation period?
    Singh R, Srivastava A, Kapoor R, Mittal RD.
    J Clin Pharmacol; 2011 Apr; 51(4):603-15. PubMed ID: 20571034
    [Abstract] [Full Text] [Related]

  • 2. Haplotypic structure of ABCB1/MDR1 gene modifies the risk of the acute allograft rejection in renal transplant recipients.
    Bandur S, Petrasek J, Hribova P, Novotna E, Brabcova I, Viklicky O.
    Transplantation; 2008 Nov 15; 86(9):1206-13. PubMed ID: 19005401
    [Abstract] [Full Text] [Related]

  • 3. Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients.
    Santoro A, Felipe CR, Tedesco-Silva H, Medina-Pestana JO, Struchiner CJ, Ojopi EB, Suarez-Kurtz G.
    Pharmacogenomics; 2011 Sep 15; 12(9):1293-303. PubMed ID: 21806386
    [Abstract] [Full Text] [Related]

  • 4. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients.
    Quteineh L, Verstuyft C, Furlan V, Durrbach A, Letierce A, Ferlicot S, Taburet AM, Charpentier B, Becquemont L.
    Basic Clin Pharmacol Toxicol; 2008 Dec 15; 103(6):546-52. PubMed ID: 19067682
    [Abstract] [Full Text] [Related]

  • 5. ABCB1 G2677 allele is associated with high dose requirement of cyclosporin A to prevent renal allograft rejection in North India.
    Singh R, Kesarwani P, Srivastava A, Mittal RD.
    Arch Med Res; 2008 Oct 15; 39(7):695-701. PubMed ID: 18760199
    [Abstract] [Full Text] [Related]

  • 6. CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on Tacrolimus dose requirements and clinical outcome after renal transplantation.
    Glowacki F, Lionet A, Buob D, Labalette M, Allorge D, Provôt F, Hazzan M, Noël C, Broly F, Cauffiez C.
    Nephrol Dial Transplant; 2011 Sep 15; 26(9):3046-50. PubMed ID: 21677300
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation.
    Niioka T, Satoh S, Kagaya H, Numakura K, Inoue T, Saito M, Narita S, Tsuchiya N, Habuchi T, Miura M.
    Transplantation; 2012 Nov 27; 94(10):1013-9. PubMed ID: 23073468
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Pharmacogenetic study of ABCB1 and CYP3A5 genes during the first year following heart transplantation regarding tacrolimus or cyclosporine levels.
    Jordán de Luna C, Herrero Cervera MJ, Sánchez Lázaro I, Almenar Bonet L, Poveda Andrés JL, Aliño Pellicer SF.
    Transplant Proc; 2011 Nov 27; 43(6):2241-3. PubMed ID: 21839244
    [Abstract] [Full Text] [Related]

  • 11. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation.
    Hauser IA, Schaeffeler E, Gauer S, Scheuermann EH, Wegner B, Gossmann J, Ackermann H, Seidl C, Hocher B, Zanger UM, Geiger H, Eichelbaum M, Schwab M.
    J Am Soc Nephrol; 2005 May 27; 16(5):1501-11. PubMed ID: 15772250
    [Abstract] [Full Text] [Related]

  • 12. Impact of CYP3A5 and CYP3A4 gene polymorphisms on dose requirement of calcineurin inhibitors, cyclosporine and tacrolimus, in renal allograft recipients of North India.
    Singh R, Srivastava A, Kapoor R, K Sharma R, D Mittal R.
    Naunyn Schmiedebergs Arch Pharmacol; 2009 Aug 27; 380(2):169-77. PubMed ID: 19343327
    [Abstract] [Full Text] [Related]

  • 13. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
    Staatz CE, Goodman LK, Tett SE.
    Clin Pharmacokinet; 2010 Apr 27; 49(4):207-21. PubMed ID: 20214406
    [Abstract] [Full Text] [Related]

  • 14. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF, Sirolimus High-Risk Study Group.
    Transplantation; 2008 Nov 15; 86(9):1187-95. PubMed ID: 19005398
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Declining intracellular T-lymphocyte concentration of cyclosporine a precedes acute rejection in kidney transplant recipients.
    Falck P, Asberg A, Guldseth H, Bremer S, Akhlaghi F, Reubsaet JL, Pfeffer P, Hartmann A, Midtvedt K.
    Transplantation; 2008 Jan 27; 85(2):179-84. PubMed ID: 18212621
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation.
    Capron A, Mourad M, De Meyer M, De Pauw L, Eddour DC, Latinne D, Elens L, Haufroid V, Wallemacq P.
    Pharmacogenomics; 2010 May 27; 11(5):703-14. PubMed ID: 20415563
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.